Physician profile
Mohammad T Ansari
NPI 1578528428
$6,163.75
in general payments reported to CMS, 2019-2025
35 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $1,393 · 2021: $554 · 2022: $496 · 2023: $670 · 2024: $756 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 200 LLC | $1,127.80 | 2019-2020 | |
| Abbott Laboratories | $813.33 | 2019-2025 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Pfizer INC. | $489.87 | 2019-2025 | |
| Amgen INC. | $363.48 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $299.30 | 2023-2025 | Watchman Flx |
| Medtronic, INC. | $288.37 | 2022-2025 | Micra, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Janssen Pharmaceuticals, INC | $200.66 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $190.86 | 2022-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $180.34 | 2019-2025 | Farxiga, Brilinta, Bevespi Aerosphere |
| Cardiovascular Systems INC. | $179.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $176.04 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $170.37 | 2019-2025 | |
| Esperion Therapeutics, INC. | $160.74 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $146.41 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Cook Medical LLC | $141.98 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.51 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $117.38 | 2019-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $115.71 | 2023-2025 | |
| Biotronik INC. | $112.53 | 2024-2025 | Biomonitor, Selectra, Amvia Edge |
| Alnylam Pharmaceuticals INC. | $107.10 | 2024 | Amvuttra |
| Biosense Webster, INC. | $105.47 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $92.97 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $85.60 | 2019-2024 | |
| Welch Allyn | $38.13 | 2021 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $32.81 | 2019 | |
| Astellas Pharma US INC | $28.05 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $23.58 | 2023 | Arcalyst |
| Medtronic Vascular, INC. | $21.88 | 2019 | |
| Abiomed | $20.93 | 2020 | |
| Philips North America LLC | $20.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.93 | 2025 | |
| Impulse Dynamics (USA) INC. | $17.46 | 2023 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $15.24 | 2019 | |
| Viiv Healthcare Company | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.